Clinical Trials
6 trialsNCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT02601950 2025-06-22
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Ipsen
Phase 2 Completed
NCT05713110 2025-01-22
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
Hutchmed
Phase 2 Completed
NCT04762160 2024-03-25
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Ipsen
Phase 2 Terminated
NCT03456726 2022-12-16
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Eisai Inc.
Phase 2 Completed
NCT02860286 2021-04-09
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Epizyme, Inc.
Phase 2 Completed